Literature DB >> 16272794

The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats.

Zahit Bolaman1, Ceyhan Cicek, Gurhan Kadikoylu, Sabri Barutca, Mukadder Serter, Cigdem Yenisey, Gulinaz Alper.   

Abstract

Free oxygen radicals and lipid peroxidation are responsible for adriamycin-induced cardiotoxicity. Amifostine is a scavenger of free radicals and may function as a selective cytoprotective agent. The aim of this study was to investigate the effects of amifostine on adriamycin-induced lipid peroxidation and the levels of protective enzymes in the heart. Male Wistar rats were randomly allocated to three groups: pretreated, untreated, and control (n=10 in each group). Rats were pretreated with an intraperitoneal injection of amifostine (200 mg/kg) 30 min before the injection of adriamycin. The pretreated rats were given an intraperitoneal injection of adriamycin (10 mg/kg) and were sacrificed after 72 h. Likewise, rats received intraperitoneal injection of adriamycin (untreated) or saline (control). The hearts were removed for the analyses of malondialdehyde (MDA), reduced glutathione (GSH) and catalase. MDA levels were increased (p<0.005) in the heart tissues of untreated rats compared to control, while GSH and catalase levels were decreased (p<0.05 and p<0.001, respectively) in untreated animals. In amifostine-preatreated group, MDA levels were lower (p<0.01), and GSH and catalase levels were higher (p<0.05 for both) than the untreated group. GSH levels were even higher in the amifostine-pretreated group compared to control (p<0.01), although catalase levels were significantly lower in the pretreated group (p<0.05). These results indicate that amifostine decreases adriamycin-induced lipid peroxidation and increases the levels of the protective enzymes in the heart tissue. Therefore, amifostine may ameliorate the adriamycin-induced acute cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272794     DOI: 10.1620/tjem.207.249

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

Review 1.  The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio A Brito-Melo; Cayo Antônio Soares de Almeida; Lázaro Lopes Moreira; Cleiton Willian Cordeiro; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

2.  Amifostine (WR2721) confers DNA protection to in vivo cisplatin-treated murine peripheral blood leukocytes.

Authors:  E A Prieto González; A G Fuchs; González S Sánchez
Journal:  Dose Response       Date:  2009-06-11       Impact factor: 2.658

3.  Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase.

Authors:  Jaroslaw Dudka; Franciszek Burdan; Agnieszka Korga; Magdalena Iwan; Barbara Madej-Czerwonka; Monika Cendrowska-Pinkosz; Agnieszka Korobowicz-Markiewicz; Barbara Jodlowska-Jedrych; Wlodzimierz Matysiak
Journal:  Oxid Med Cell Longev       Date:  2012-08-23       Impact factor: 6.543

4.  Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.

Authors:  Hong Zhu; Peihua Luo; Yingying Fu; Jincheng Wang; Jiabin Dai; Jinjin Shao; Xiaochun Yang; Linlin Chang; Qinjie Weng; Bo Yang; Qiaojun He
Journal:  Oncotarget       Date:  2015-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.